

HR 2376

Drug Diversion and Counterfeit Crackdown Act of 2017

Congress: 115 (2017–2019, Ended)

Chamber: House

Policy Area: Health

Introduced: May 4, 2017

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (May 5, 2017)

Official Text: <https://www.congress.gov/bill/115th-congress/house-bill/2376>

Sponsor

Name: Rep. Lance, Leonard [R-NJ-7]

Party: Republican • **State:** NJ • **Chamber:** House

Cosponsors (3 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Burgess, Michael C. [R-TX-26]	R · TX		May 4, 2017
Rep. Dingell, Debbie [D-MI-12]	D · MI		May 4, 2017
Rep. Green, Gene [D-TX-29]	D · TX		May 4, 2017

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	May 5, 2017

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
115 HR 2430	Related bill	Aug 18, 2017: Became Public Law No: 115-52.
115 S 934	Related bill	May 11, 2017: Placed on Senate Legislative Calendar under General Orders. Calendar No. 76.

Summary (as of May 4, 2017)

Drug Diversion and Counterfeit Crackdown Act of 2017

This bill makes it illegal except in cases of a drug shortage to import into the United States prescription drugs manufactured outside the United States and intended by the manufacturer or labeled to be marketed outside the United States.

The bill establishes a penalty for knowingly dispensing or selling a counterfeit drug.

Actions Timeline

- **May 5, 2017:** Referred to the Subcommittee on Health.
- **May 4, 2017:** Introduced in House
- **May 4, 2017:** Referred to the House Committee on Energy and Commerce.